000303370 001__ 303370
000303370 005__ 20250806114414.0
000303370 0247_ $$2doi$$a10.1186/s13014-025-02707-7
000303370 0247_ $$2pmid$$apmid:40745612
000303370 0247_ $$2pmc$$apmc:PMC12315396
000303370 037__ $$aDKFZ-2025-01619
000303370 041__ $$aEnglish
000303370 082__ $$a610
000303370 1001_ $$00000-0001-7370-5077$$aJabbarli, Leyla$$b0
000303370 245__ $$aAnatomical outcome after brachytherapy with bi-nuclide (Ru-106/Iodine-125) plaques in large uveal melanomas.
000303370 260__ $$aLondon$$bBioMed Central$$c2025
000303370 3367_ $$2DRIVER$$aarticle
000303370 3367_ $$2DataCite$$aOutput Types/Journal article
000303370 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1754393742_8393
000303370 3367_ $$2BibTeX$$aARTICLE
000303370 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303370 3367_ $$00$$2EndNote$$aJournal Article
000303370 520__ $$aProprietary bi-nuclide plaques combine the radiation properties of beta and gamma brachytherapy and can irradiate a larger target volume compared to ruthenium-plaques. While reducing the dose to structures outside the target volume, brachytherapy with bi-nuclide-plaques (BBNP) delivers a higher target dose compared to iodine-plaques. We aimed at analyzing the local tumor control and eye retention probability after BBNP.All consecutive cases with large uveal melanoma (tumor thickness ≥ 7 mm) treated with BBNP at our institution between 01/1999 and 12/2020 were included (n = 576, median follow-up: 30.8 months [interquartile range, IQR: 12.9-57.4]). Univariable and multivariable Cox regression analyses were performed.Secondary enucleation (SE) was performed in 13.5% of cases (n = 78) after the median of 20.0 months (IQR: 9.0-34.7) post-BBNP. The overall rate of local tumor recurrence (LR) in the cohort was 8.5% (n = 49) and was diagnosed at the median post-BBNP interval of 20.0 months (IQR: 15.6-35.2). Of the patients' baseline characteristics, higher age (> 67 years, adjusted hazard ratio [aHR] = 1.80, p = 0.011), tumor thickness (> 8.5 mm, aHR = 2.20, p = 0.002), visual acuity (> 0.5 logMAR, aHR = 1.83, p = 0.009), and sclera dose (> 1000 Gy, aHR = 1.65, p = 0.034) were independently associated with the risk of SE. In turn, higher age (> 67 years, aHR = 1.93, p = 0.023), tumor thickness (> 8.5 mm, aHR = 2.02, p = 0.020), and visual acuity (> 0.5 logMAR, aHR = 2.27, p = 0.005) were independently related to LR.BBNP facilitates eye retention in 86.5% of patients with large uveal melanoma 2.5 years after treatment. Patients' baseline, tumor and treatment characteristics were strongly associated with the risk of SE and LR after BBNP.
000303370 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000303370 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303370 650_7 $$2Other$$aBi-nuclide plaque
000303370 650_7 $$2Other$$aBrachytherapy
000303370 650_7 $$2Other$$aEnucleation
000303370 650_7 $$2Other$$aLocal recurrence
000303370 650_7 $$2Other$$aRisk factors
000303370 650_7 $$2Other$$aUveal melanoma
000303370 650_7 $$2NLM Chemicals$$aIodine Radioisotopes
000303370 650_7 $$2NLM Chemicals$$aRuthenium Radioisotopes
000303370 650_7 $$0GVO776611R$$2NLM Chemicals$$aIodine-125
000303370 650_7 $$2NLM Chemicals$$aRuthenium-106
000303370 650_2 $$2MeSH$$aHumans
000303370 650_2 $$2MeSH$$aBrachytherapy: methods
000303370 650_2 $$2MeSH$$aUveal Neoplasms: radiotherapy
000303370 650_2 $$2MeSH$$aUveal Neoplasms: pathology
000303370 650_2 $$2MeSH$$aMelanoma: radiotherapy
000303370 650_2 $$2MeSH$$aMelanoma: pathology
000303370 650_2 $$2MeSH$$aMale
000303370 650_2 $$2MeSH$$aIodine Radioisotopes: therapeutic use
000303370 650_2 $$2MeSH$$aUveal Melanoma
000303370 650_2 $$2MeSH$$aFemale
000303370 650_2 $$2MeSH$$aMiddle Aged
000303370 650_2 $$2MeSH$$aRuthenium Radioisotopes: therapeutic use
000303370 650_2 $$2MeSH$$aAged
000303370 650_2 $$2MeSH$$aRetrospective Studies
000303370 650_2 $$2MeSH$$aAdult
000303370 650_2 $$2MeSH$$aFollow-Up Studies
000303370 650_2 $$2MeSH$$aAged, 80 and over
000303370 650_2 $$2MeSH$$aNeoplasm Recurrence, Local: pathology
000303370 650_2 $$2MeSH$$aRadiotherapy Dosage
000303370 650_2 $$2MeSH$$aPrognosis
000303370 7001_ $$aFiorentzis, Miltiadis$$b1
000303370 7001_ $$0P:(DE-HGF)0$$aGuberina, Maja$$b2
000303370 7001_ $$aSchmidt, Boerge$$b3
000303370 7001_ $$aRating, Philipp$$b4
000303370 7001_ $$aBiewald, Eva$$b5
000303370 7001_ $$0P:(DE-HGF)0$$aGuberina, Nika$$b6
000303370 7001_ $$aFlühs, Dirk$$b7
000303370 7001_ $$aBornfeld, Norbert$$b8
000303370 7001_ $$aSauerwein, Wolfgang$$b9
000303370 7001_ $$0P:(DE-HGF)0$$aStuschke, Martin$$b10
000303370 7001_ $$aBechrakis, Nikolaos E$$b11
000303370 773__ $$0PERI:(DE-600)2224965-5$$a10.1186/s13014-025-02707-7$$gVol. 20, no. 1, p. 119$$n1$$p119$$tRadiation oncology$$v20$$x1748-717X$$y2025
000303370 909CO $$ooai:inrepo02.dkfz.de:303370$$pVDB
000303370 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000303370 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000303370 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000303370 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000303370 9141_ $$y2025
000303370 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIAT ONCOL : 2022$$d2024-12-18
000303370 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000303370 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000303370 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:44:48Z
000303370 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:44:48Z
000303370 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:44:48Z
000303370 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-18
000303370 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-18
000303370 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000303370 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000303370 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000303370 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000303370 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000303370 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000303370 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
000303370 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
000303370 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000303370 980__ $$ajournal
000303370 980__ $$aVDB
000303370 980__ $$aI:(DE-He78)ED01-20160331
000303370 980__ $$aUNRESTRICTED